Thomas Butler, MD
Hematology & Oncology · Mobile, ALNPI 1396787230
Payments from drug & device makers
Across 74 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$328
- Genentech, Inc.$267
- Pfizer$151
- AbbVie$128
- Johnson & Johnson$91
- Immunocore Limited$67
- plus $566 from 18 others
What the payments were for
- Food & beverage$1,30281%
- Education$29619%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 20 | $328 |
| Genentech, Inc. | 5 | $267 |
| Pfizer | 8 | $151 |
| AbbVie | 5 | $128 |
| Johnson & Johnson | 2 | $91 |
| Immunocore Limited | 2 | $67 |
| Amgen | 4 | $60 |
| Octapharma USA, Inc. | 2 | $43 |
| Gilead | 3 | $43 |
| Pharmaessentia USA Corporation | 2 | $41 |
| Merck | 2 | $40 |
| AstraZeneca | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Array Biopharma Inc | 2 | $34 |
| Eisai Inc. | 2 | $33 |
| ADC Therapeutics America, Inc. | 1 | $24 |
| Genentech USA, Inc. | 2 | $23 |
| Sanofi | 1 | $21 |
| GSK | 1 | $20 |
| Cumberland Pharmaceuticals, Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $20 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
How this compares
$1,598 in reported general payments places this provider in the 15th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 33 | $28,574 |
| OxycontinOxycodone Hcl | 11 | $19,953 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 356 | $14,763 |
| Fentanyl | 118 | $14,053 |
| Morphine Sulfate ErMorphine Sulfate | 206 | $11,944 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 240 | $11,713 |
| Oxycodone Hcl | 246 | $6,848 |
| Gabapentin | 254 | $3,375 |
| Hydromorphone Hcl | 86 | $2,926 |
| Pregabalin | 34 | $2,600 |
| Methadone Hcl | 53 | $2,060 |
| Morphine Sulfate | 27 | $1,589 |
| Duloxetine Hcl | 16 | $324 |
| Clonazepam | 46 | $320 |
| Alprazolam | 53 | $281 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Mobile
- Michael MeshadMobile$5.3M
- Jose Galeas SorianoMobile$536K
- Anita MazloomMobile$454K
- Sherri ArledgeMobile$358K
- Brian HellerMobile$213K
- Thaddeus BeekerMobile$195K
- Prajwol PathakMobile$158K
- Ahmed AbdallaMobile$141K
- Luciano CostaBirmingham$32.8M
- Amitkumar MehtaBirmingham$18.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.